08/19/2021
Research Article
EGFRAP encodes a new negative regulator of the EGFR acting in both normal and oncogenic EGFR/Ras-driven tissue morphogenesis
Soler Beatty et al. identify a novel EGFR inhibitor, EGFRAP, which is an important limiter of tumor growth driven by oncogenic EGFR/Ras activity. They suggest that the ability of EGFRAP to functionally inhibit the EGFR pathway in oncogenic cells results from the activation of a feedback loop leading to increased EGFRAP expression.
Image credit: Jennifer Soler Beatty & María D. Martín-Bermudo
Connect with Us